Cancer Genetics Inc (CGIX) Stake Held by Sabby Healthcare Master Fund, Ltd
January 20th, 2016 - 0 comments - Filed Under - by John Ramos
Cancer Genetics logoSabby Healthcare Master Fund, Ltd disclosed that they own 5% of Cancer Genetics Inc (NASDAQ:CGIX) in a Schedule 13G/A disclosure that was filed with the SEC on Thursday, January 14th. The investor owns 531,531 shares of the stock valued at about $1,084,323. The reporting parties listed on the disclosure included Sabby Healthcare Master Fund, Ltd, Sabby Volatility Warrant Master Fund, Ltd, Sabby Management, LLC and Hal Mintz. The filing is available through the SEC website at this link.
Shares of Cancer Genetics Inc (NASDAQ:CGIX) opened at 2.04 on Wednesday. The company has a 50-day moving average of $2.89 and a 200-day moving average of $7.06. Cancer Genetics Inc has a 12-month low of $1.90 and a 12-month high of $12.75. The stock’s market capitalization is $21.73 million.
Cancer Genetics (NASDAQ:CGIX) last announced its earnings results on Tuesday, November 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.49) by $0.07. During the same period in the previous year, the company earned ($0.51) EPS. The company had revenue of $4 million for the quarter, compared to analysts’ expectations of $5.13 million. The firm’s quarterly revenue was up 25.0% compared to the same quarter last year. Equities analysts expect that Cancer Genetics Inc will post ($1.94) earnings per share for the current fiscal year.
A number of equities research analysts have recently commented on CGIX shares. Zacks Investment Research upgraded shares of Cancer Genetics from a “hold” rating to a “strong-buy” rating and set a $9.00 price target for the company in a report on Tuesday, October 13th. Aegis reiterated a “positive” rating on shares of Cancer Genetics in a report on Tuesday, October 6th.
Cancer Genetics, Inc. is an oncology diagnostics company focused on developing, commercializing and providing DNA-based tests and services. The business is based on demand for DNA-based diagnostic services from three main sectors, including cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community. Its clinical offerings include its portfolio of proprietary tests targeting hematological, urogenital and HPV-associated cancers, in conjunction with ancillary non-proprietary tests. Biopharma services include laboratory and testing services performed for biopharmaceutical companies engaged in clinical trials. Discovery services provide the tools and testing methods for companies and researchers seeking to identify new DNA-based biomarkers for disease.
